# Efficacy and Safety of Insulin Lispro Biphasic 25 Compared to Humalog® Mix 25 in Type 2 Diabetes Mellitus Patients

Study · id `cardio:ct-nct04023344` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04023344](<https://clinicaltrials.gov/study/NCT04023344>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04023344

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 210 participants.

## Technical summary

Registry record NCT04023344. Randomized; no masking; primary purpose treatment. Start 2018-03-14 (actual); primary completion 2019-01-15 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 210 participants (enrolled count; ClinicalTrials.gov record NCT04023344, source copy `cardio:ctgov-nct04023344-2019-07-17`, retrieved 2026-10-26)
- Started: 2018-03-14 (actual) (ClinicalTrials.gov record NCT04023344, source copy `cardio:ctgov-nct04023344-2019-07-17`, retrieved 2026-10-26)
- Primary completion: 2019-01-15 (actual) (ClinicalTrials.gov record NCT04023344, source copy `cardio:ctgov-nct04023344-2019-07-17`, retrieved 2026-10-26)
- Completion: 2019-04-18 (actual) (ClinicalTrials.gov record NCT04023344, source copy `cardio:ctgov-nct04023344-2019-07-17`, retrieved 2026-10-26)
- Countries: Russia (ClinicalTrials.gov record NCT04023344, source copy `cardio:ctgov-nct04023344-2019-07-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04023344-2019-07-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Insulin Lispro Biphasic 25 Compared to Humalog® Mix 25 in Type 2 Diabetes Mellitus Patients
- Condition: Diabetes Mellitus, Type 2
- Condition: Diabetes Mellitus
- Intervention (Drug): Humalog Mix25
- Intervention (Drug): Insulin Lispro Biphasic 25
- Lead sponsor: Geropharm
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Geropharm (`cardio:org-geropharm`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and safety of GP40021 insulin lispro biphasic compared with Humalog Mix 25 in Type 2 diabetes mellitus patients (`cardio:pubmed-33355484`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 10d9d800520e2b9b2157ee5d518266734002ef87d6d52a41b1b114fb97a8bd9b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
